Haemodynamic effects of levosimendan for low cardiac output after cardiac surgery: A case series

Hellenic Journal of Cardiology

Volumn 48, Issue 2, 2007, Pages 80-88

  Malliotakis, Polychronis ^a   Xenikakis, Theophilos ^a   Linardakis, Manolis ^b   Hassoulas, John ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Calcium sensitizers; Cardiopulmonary bypass; Heart failure; Inotropes

Indexed keywords

DOBUTAMINE; LEVOSIMENDAN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARDIOTONIC AGENT; CATECHOLAMINE; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CARDIAC OUTPUT SYNDROME; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART DISEASE; HEART HEMODYNAMICS; HEART INDEX; HEART OUTPUT; HEART SURGERY; HUMAN; LOADING DRUG DOSE; MALE; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD PRESSURE; CARDIOPULMONARY BYPASS; DRUG COMBINATION; FORWARD HEART FAILURE; GREECE; HEART CONTRACTION; HEART RATE; HEART STROKE VOLUME; METHODOLOGY; MIDDLE AGED; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; TIME; VASCULAR RESISTANCE;

ADRENERGIC BETA-AGONISTS; AGED; BLOOD PRESSURE; CARDIAC OUTPUT, LOW; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CARDIOTONIC AGENTS; CATECHOLAMINES; DOBUTAMINE; DRUG THERAPY, COMBINATION; FEMALE; GREECE; HEART DISEASES; HEART RATE; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; OXYGEN CONSUMPTION; PYRIDAZINES; RESEARCH DESIGN; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 34548077199     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Breisblatt WM, Stein KL, Wolfe CJ, et al: Acute myocardial dysfunction and recovery: a common occurrence after coronary bypass surgery. J Am Coll Cardiol 1990; 15: 1261-1269.
2. Doyle AR, Dhir AK, Moors AH, et al: Treatment of perioperative low cardiac output syndrome. Ann Thorac Surg 1995; 59: S3-11.
3. Rao V, Ivanov J, Weisel RD, et al: Predictors of low cardiac output syndrome after coronary artery bypass. J Thorac Cardiovasc Surg 1996; 112: 38-51.
4. Butterworth JF, Legault C, Royster RL, et al: Factors that predict the use of positive inotropic drug support after cardiac valve surgery. Anesth Analg 1998; 86: 461-467.
5. Romson JL, Leung JM, Bellows WH, et al: Effects of dobutamine on hemodynamics and left ventricular performance after cardiopulmonary bypass in cardiac surgical patients. Anesthesiology 1999; 91: 1318-1328.
6. Levy JH, Bailey JM, Deeb GM: Intravenous milrinone in cardiac surgery. Ann Thorac Surg 2002; 73: 325-330.
7. Figgitt DP, Gillies PS, Goa KL: Levosimendan. Drugs 2001; 61: 613-627.
8. McBride BF, White CM: Levosimendan: implications for clinicians. J Clin Pharmacol 2003; 43: 1071-1081.
9. Frishman WH: Advances in positive inotropic therapy: Levosimendan. Crit Care Med 2003; 31: 2408-2409.
10. Lehtonen L: Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties. Expert Opin Investig Drugs 2001; 10: 955-970.
11. Kersten JR, Montgomery MW, Pagel PS: Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000; 90: 5-11.
12. Janssen P M L, Datz N, Zeitz O, et al: Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol 2000; 404: 191-199.
13. De Luca L, Sardella G, Proietti P, et al: Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echocardiographic study. J Am Soc Echocardiogr 2006; 19: 172-177.
14. Parissis JT, Panou F, Farmakis D, et al: Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005; 96; 423-426.
15. Givertz MM, Andreou C, Conrad CH, et al: Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: Alteration of force-frequency and relaxation-frequency relationships. Circulation 2007; 115; 1218-1224.
16. Follath F, Cleland JG, Just H, et al: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output cardiac failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202.
17. Singh BN, Lilleberg J, Sandell EP, et al: Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failure. Am J Cardiol 1999; 83: (I)16-20.
18. Moiseyev VS, Poder P, Andrejevs N, et al: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422-1432.
19. Lilleberg J, Ylonen V, Lehtonen L, et al: The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J 2004; 38: 80-84.
20. Flevari P, Parissis JT, Leftheriotis D, et al: Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol 2006; 98: 1641-1645.
21. Nieminen MS, Bohm M, Cowie MR, et al: Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416.
22. Lilleberg J, Nieminen MS, Akkila J, et al: Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998; 19: 660-668.
23. Nijhawan N, Nicolosi AC, Montgomery MW, et al: Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1998; 34: 219-228.
24. Labriola C, Siro-Brigiani M, Carrata F, et al: Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 2004; 42: 204-211.
25. Siirila-Waris K, Suojaranta-Ylinen R, Harjola VP: Levosimendan in cardiac surgery. J Cardiothorac Vasc Anesth 2005; 19; 345-349.
26. Alvarez J, Bouzada M, Fernandez AL, et al: Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery. Rev Esp Cardiol 2006; 59: 338-345.
27. Plochl W, Rajek A: The use of the novel calcium sensitizer levosimendan in critically ill patients. Anaesth Intensive Care 2004; 32:471-475.
28. Nashef SA, Roques F, Michel P, et al: European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999; 16: 9-13.
29. Packer M: The search for the ideal positive inotropic agent. N Engl J Med 1993; 329: 201-202.
30. Mollhoff T, Loick HM, van Aken H, et al: Milrinone modulates endotoxemia, systemic inflammation and subsequent acute phase response after cardiopulmonary bypass (CPB). Anesthesiology 1999; 90: 72-80.
31. Laffey JG, Boyland JF, Cheng DC: The systemic inflammatory response to cardiac surgery. Anesthesiology 2002; 97: 215-252.
32. Royster RL, Butterworth JF, Prough DS, et al: Preoperative and intraoperative predictors of inotropic support and long-term outcome in patients having coronary artery bypass grafting. Anesth Analg 1991; 72: 729-736.
33. Bernard F, Denault A, Babin D, et al: Diastolic dysfunction is predictive of difficult weaning from cardiopulmonary bypass. Anesth Analg 2001; 92: 291-298.
34. Tuman KJ, McCarthy RJ, O'Connor CJ, et al: Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anesth Analg 1995; 80: 473-479.
35. Hardy JF, Belisle S: Inotropic support of the heart that fails to successfully wean from cardiopulmonary bypass: the Montreal Heart Institute experience. J Cardiothorac Vasc Anesth 1993; 7: 33-39.
36. Nanas JN, Papazoglou PP, Terrovitis JV, et al: Haemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol 2004; 94: 1329-1332.
37. Delle Karth G, Buberl A, Geppert A, et al: Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 2003; 47: 1251-1256.
38. Braun JP, Jasulaitis D, Moshirzadeh M, et al: Levosimendan may improve survival in patients requiring mechanical assist devices for post-cardiotomy heart failure. Critical Care 2006; 10: R17.